Elanco
Elanco is a global animal-health company developing medicines, vaccines, parasiticides, nutritional products, and sustainability solutions for pets and food-producing animals.
Last updated October 14, 2026
AI crawler reads
1requests
1companies- Anthropic1
- Profile
- 1
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
Since Oct 28, 2026 · from this site's server log
Overview
Elanco is an American animal-health company whose products are used in companion animals, livestock, and aquaculture. Its portfolio spans prescription medicines, vaccines, parasiticides, feed additives, diagnostics-related services, and nutritional or production technologies. The company serves veterinarians, pet owners, farmers, food producers, distributors, and animal-health professionals in markets around the world. The business traces its origins to Eli Lilly and Company's early veterinary and agricultural research. In 1953, Lilly introduced an antibiotic for veterinary use and combined plant and animal-science activities within an agro-industrial division. During the 1960s, the operation adopted the Elanco name, derived from Eli Lilly and Company. Although the business initially included plant-science work, its strategic direction gradually moved toward animal health and food quality. By the 1990s, it had been reorganized as Elanco Animal Health and was focused primarily on medicines and related products for animals. Elanco expanded through a combination of internal research, licensing, partnerships, and acquisitions. The purchase of Ivy Animal Health in 2007 strengthened its companion-animal activities. During the following decade, it added products and capabilities through transactions involving Pfizer Animal Health rights, Janssen Animal Health, ChemGen, Lohmann Animal Health, Novartis Animal Health, and selected Boehringer Ingelheim vaccine assets. The Novartis transaction was particularly significant because it broadened Elanco's presence across pet, livestock, and vaccine categories. Elanco also developed Elanco Knowledge Solutions, a data and analytics business intended to help food-animal producers improve operational and production decisions. The company became independent from Eli Lilly through a 2018 initial public offering plan and a 2019 separation. It began trading on the New York Stock Exchange under the symbol ELAN. Independence enabled Elanco to pursue a more concentrated animal-health strategy and a more active acquisition program. In 2019 it acquired Aratana Therapeutics, adding companion-animal medicines including products associated with canine osteoarthritis, and announced the acquisition of Prevtec Microbia, a developer of bacterial-disease prevention technologies for food animals. It also agreed to acquire Bayer's animal-health business, a transaction completed in 2020 that materially expanded its pet-health and livestock portfolio. The Bayer transaction brought brands such as Seresto and Credelio into Elanco's portfolio, while later acquisitions added further companion-animal research and commercial capabilities. In 2021, Elanco completed its purchase of KindredBio, known as Kindred Biosciences, strengthening its pipeline and specialty-pet focus. The company has also invested in a new global headquarters campus in Indianapolis, designed as part of a broader animal-health innovation district. Elanco's commercial strategy is commonly organized around two major areas: pet health and farm-animal health. Pet-health products address parasitic disease, dermatology, pain, osteoarthritis, and preventive care. Farm-animal products include vaccines, anti-infectives, feed additives, and technologies intended to improve animal productivity, disease control, and sustainability. In 2024, Elanco emphasized newer growth products such as Zenrelia and Credelio Quattro, and it positioned Bovaer, a methane-reducing feed ingredient for dairy cattle, as part of its sustainability offering. The company operates under a corporate-responsibility framework called Healthy Purpose. Its stated priorities include supporting food security, helping farmers reduce environmental impacts, and advancing animal welfare and health. In 2024, Elanco sold its aquaculture business and related assets to Merck Animal Health for approximately $1.3 billion in cash, reflecting a strategic decision to concentrate on pet health and livesto…
History
Elanco began within Eli Lilly and Company's agricultural and veterinary research activities. In 1953, Lilly introduced a veterinary antibiotic and combined plant- and animal-science work under an agro-industrial organization led by George Barnes. During the 1960s, the business was reorganized as Elanco Products, a name derived from Eli Lilly and Company. The operation initially covered both plant science and animal science. During the 1980s, however, its research emphasis moved away from plant sciences and toward animal health and food quality. A further reorganization in the 1990s produced Elanco Animal Health, with the business focused on animal medicines, vaccines, and related technologies. Elanco began building a larger companion-animal presence through the acquisition of Ivy Animal Health in 2007. In 2008 it entered a partnership with Heifer International, and in 2009 it launched Elanco Knowledge Solutions, a data and analytics activity for the food-animal sector. Further expansion followed in Europe and livestock health: Elanco acquired European rights to a Pfizer Animal Health product portfolio and an Irish manufacturing site in 2010, purchased Janssen Animal Health in 2011, and acquired ChemGen in 2012. The company accelerated its acquisition program in 2014. It purchased Lohmann SE and Lohmann Animal Health and acquired Novartis Animal Health for $5.4 billion. The Novartis transaction broadened Elanco's international reach and added important companion-animal and livestock products. In 2013, before those transactions, Elanco had also invested $100 million in China Animal Healthcare. In 2016, it acquired selected vaccines from Boehringer Ingelheim Vetmedica for $885 million. Eli Lilly announced in 2018 that it intended to separate Elanco through a public offering. Elanco began trading independently on the New York Stock Exchange in 2019 under the symbol ELAN. That year brought several strategic developments: the U.S. Food and Drug Administration approved rabacfosadine for canine lymphoma; Elanco acquired Aratana Therapeutics; it announced the acquisition of Prevtec Microbia; and it agreed to buy Bayer's animal-health business for $7.6 billion. The Bayer transaction closed in 2020 and added major pet-health and livestock brands, including Seresto and Credelio. In December 2020, Elanco announced plans for a new global headquarters in Indianapolis on the site of a former General Motors stamping plant. Construction officially began in April 2022. The project was associated with an animal-health innovation district and was intended to create a central location for the company's global operations and research-oriented activities. Elanco acquired Kindred Biosciences in 2021, adding development programs and expertise in companion-animal medicines. The company subsequently faced scrutiny concerning Seresto flea and tick collars. A 2022 report by a U.S. House Oversight and Reform subcommittee cited tens of thousands of reported pesticide-poisoning incidents and more than 2,000 reported pet deaths. In July 2023, after a multi-year review, the EPA said it could not establish that Seresto caused the reported deaths. The agency nevertheless limited the collar's registration to five years rather than the usual fifteen and agreed with Elanco on enhanced adverse-event monitoring and annual reporting. In 2024, Elanco pursued a sharper strategic focus on higher-value pet health and livestock sustainability. It sold its aquaculture business, including related products and manufacturing sites, to Merck Animal Health for approximately $1.3 billion in cash. Its newer commercial priorities included Zenrelia for canine dermatology, Credelio Quattro for broad parasite protection, and Bovaer, a feed ingredient intended to reduce methane emissions from dairy cattle. Elanco continues to operate as a global animal-health company with businesses serving both companion animals and food-producing animals.
- 2024
Aquaculture business divested
[1]Elanco sold its aquaculture activities to Merck Animal Health as part of a portfolio-focus strategy.
- 2021
Kindred Biosciences acquired
[1]Elanco added a specialty companion-animal development platform.
- 2020
Bayer Animal Health acquisition completed
[1]The transaction substantially increased Elanco's scale in companion-animal and livestock health.
- 2019
Elanco becomes an independent public company
[1]Following its separation from Eli Lilly, Elanco began trading on the New York Stock Exchange under ELAN.
- 2014
Novartis Animal Health acquired
[1]Elanco completed a major acquisition that expanded its global pet and livestock-health portfolio.
- 2007
Ivy Animal Health acquired
[1]The acquisition strengthened Elanco's companion-animal business.
- 1990
Focus narrows to animal health
[1]A reorganization renamed the business Elanco Animal Health and concentrated it on animal-health activities.
- 1960
Elanco Products name emerges
[1]Lilly's agro-industrial activities were reorganized and the Elanco Products name came into use.
- 1953
Lilly introduces a veterinary antibiotic
[1]Eli Lilly introduced its first antibiotic aimed at veterinary use, establishing an important foundation for the later Elanco business.
Products and positioning
A research-driven global animal-health company combining companion-animal therapeutics and preventive care with livestock medicines, vaccines, feed technologies, and sustainability solutions.
Pet parasiticide collar
Seresto
A long-duration flea and tick collar for dogs and cats. The product entered Elanco's portfolio through the Bayer Animal Health acquisition and became one of the company's best-known companion-animal brands. Its regulatory and safety reporting history has also made it a subject of public and governmental scrutiny.
Oral pet parasiticide
Credelio
An oral lotilaner-based treatment for dogs and cats that provides flea and tick control. It is positioned as a convenient systemic parasiticide within Elanco's companion-animal preventive-care portfolio.
Broad-spectrum pet parasiticide · 2024
Credelio Quattro
A newer parasiticide product designed to combine protection against fleas, ticks, heartworm, and tapeworms. Elanco presents it as a next-generation companion-animal product with broad preventive coverage.
Canine and feline parasite preventive
Interceptor Plus
A monthly chewable preventive used to prevent heartworm disease and treat or control several common intestinal parasites in dogs. It represents Elanco's established preventive-care offering for companion animals.
Canine osteoarthritis medicine
Galliprant
A prescription medicine for pain and inflammation associated with osteoarthritis in dogs. It is described as a first-in-class piprant and is an important example of Elanco's focus on specialty companion-animal therapeutics.
Livestock feed additive
Rumensin
A feed ingredient used in cattle production to improve feed efficiency and help prevent coccidiosis. The brand illustrates Elanco's long-standing presence in food-animal productivity and disease-management products.
Canine dermatology medicine · 2024
Zenrelia
A once-daily oral treatment for canine dermatology indications. Elanco identified Zenrelia as one of its newer potential blockbuster products and part of its effort to expand higher-value pet-health therapies.
Livestock sustainability feed ingredient · 2024
Bovaer
A feed ingredient for dairy cattle intended to reduce methane emissions. Elanco positions Bovaer as a sustainability-oriented livestock technology supporting efforts to reduce the environmental footprint of food production.
Controversies
2023
EPA review of Seresto adverse-event reports
After a multi-year review, the EPA said it could not determine that Seresto caused the reported animal deaths. It nevertheless shortened the product's registration period and required enhanced adverse-event data collection and reporting arrangements.
2022
Seresto collar safety allegations
A U.S. House Oversight and Reform subcommittee report cited tens of thousands of reported pesticide-poisoning incidents involving Seresto collars, including more than 2,000 reported pet deaths. The report generated scrutiny of Elanco's product-safety reporting and regulatory oversight.
Marketing campaigns
- 2020Healthy Purpose
International
Elanco organized its corporate-responsibility work under the Healthy Purpose framework, addressing animal welfare, food security, farmer support, and environmental sustainability.
Outcome. The framework became the stated basis for 2030 ambitions, including support for food security and a net-zero operations goal.
- 2009Elanco Knowledge Solutions
International
Elanco launched a data and analytics business intended to help food-animal producers make better operational and production decisions.
Outcome. The initiative broadened Elanco's offering beyond medicines and vaccines into information-enabled animal production services.
- 2008Heifer International partnership
International
Elanco partnered with Heifer International in an initiative connected with livestock, farming livelihoods, and food security.
Outcome. The partnership established an early example of Elanco's externally oriented social-responsibility activity.
Brand decisions
2024
Concentrate on pet health and livestock sustainabilityStrategyBackground
Elanco announced a portfolio strategy emphasizing higher-value pet-health products and livestock sustainability initiatives.
Action taken
The company sold its aquaculture business and associated manufacturing assets to Merck Animal Health.
Aftermath
The divestiture reduced Elanco's exposure to aquaculture and supported a more focused animal-health portfolio.
Cash consideration. Approximately $1.3 billion (2024 transaction)
2019
Acquire Bayer Animal HealthM&ABackground
Elanco sought to increase its scale and broaden its companion-animal and livestock-health portfolio.
Action taken
Elanco announced an agreement to acquire Bayer's animal-health business for approximately $7.6 billion.
Aftermath
The transaction closed in 2020 and added major products, manufacturing capabilities, and international reach.
Announced transaction value. $7.6 billion (2019 announcement)
2018
Separate Elanco from Eli LillyStrategyBackground
Elanco had operated as a subsidiary of Eli Lilly, but Lilly sought to make the animal-health business an independently traded company.
Action taken
Lilly announced an initial public offering and separation plan for Elanco.
Aftermath
Elanco completed the separation in 2019 and began trading on the New York Stock Exchange under ELAN.
Recent events
Reported
TriRx completes acquisition of Elanco's Speke manufacturing facility[2]
TriRx completed its acquisition of ownership and operations of Elanco's manufacturing site in Speke, United Kingdom; TriRx officially took ownership on February 1, 2022.
Reported
TriRx and Elanco enter long-term supply agreement[3]
TriRx and Elanco entered into a long-term supply agreement for the Shawnee site to ensure continued supply of Elanco products.
Reported
TriRx completes acquisition of Elanco's Shawnee facility[3]
TriRx completed its acquisition of ownership and operations of Elanco's Shawnee, Kansas manufacturing site. The sale included the site's physical assets and employment of approximately 300 personnel.
Reported
MSD completes acquisition of Vecoxan worldwide rights[4]
MSD Animal Health completed its $55 million acquisition from Elanco Animal Health of the worldwide rights to Vecoxan, an oral suspension used to prevent and treat coccidiosis in calves and lambs.
Reported
Elanco completes acquisition of Bayer Animal Health[5]
Elanco completed its acquisition of Bayer Animal Health on Monday. The deal was valued at $6.9 billion.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
- Unconfirmed
Reported
Dechra completes acquisition of worldwide Osurnia rights[6]
Dechra Pharmaceuticals completed its acquisition of the worldwide rights to the Osurnia product portfolio from Elanco Animal Health for USD 135.0 million (£104.7 million).
Reported
Neogen plans to acquire U.S. rights to Elanco's StandGuard Pour-on[7]
Neogen plans to acquire the U.S. rights to Elanco's StandGuard Pour-on and related assets. The transaction had not yet closed; the article said closing remained subject to a final Federal Trade Commission consent relating to Elanco's acquisition of Bayer's global animal health business.
Reported
VetNOW partners with Elanco to provide veterinary telehealth access[8]
VetNOW partnered with Elanco Animal Health to provide veterinarians access to VetNOW's telehealth platform, including specialist consultations; the article says about 12,000 veterinarians are expected to be onboarded in the coming months.
Reported
Dechra agrees to acquire worldwide rights to Osurnia[9]
Dechra announced that it had agreed terms to acquire the worldwide rights to Elanco's Osurnia product portfolio for USD 135.0 million. Completion was expected before the end of June 2020, subject to conditions and regulatory approvals.
Reported
Elanco sells its Victoria aquaculture R&D facility to CATC[10]
Elanco sold its aquaculture research and development facility in Victoria, Prince Edward Island, to the Center for Aquaculture Technologies Canada (CATC). The article says the transaction was expected to close in early 2020, so it reports a sale agreement rather than a completed closing.
Sources10 sources
- 1Elancoen.wikipedia.org
- 2TriRx完成对Elanco斯皮克制造工厂的收购prnewswire.com
- 3TriRx与Elanco达成长期供应协议prnewswire.com
- 4MSD完成收购Vecoxan全球权利agriland.ie
- 5Elanco完成对拜耳动物保健业务的收购hoosieragtoday.com
- 6Dechra 完成 Osurnia 全球权利收购directorstalkinterviews.com
- 7Neogen 计划收购 Elanco 的 StandGuard Pour-on 美国权利dbusiness.com
- 8VetNOW与Elanco合作提供兽医远程医疗服务nextpittsburgh.com
- 9Dechra同意收购Osurnia全球权利directorstalkinterviews.com
- 10Elanco 将维多利亚水产研发设施出售给 CATCveterinarypracticenews.com
Cite this profile: Cite the canonical profile. /brand-wiki/elanco · Editorial policy · How profiles are compiled